6/20/2013

Cambridge, Mass.-based firm bluebird bio plans to initiate in U.S. and Europe this year a Phase II/III clinical trial for Lenti-D, its lead drug candidate for childhood cerebral adrenoleukodystrophy. Lenti-D won orphan drug status in Europe and the U.S. last year.

Related Summaries